Boston Scientific to sell BTG Specialty Pharmaceuticals for $800M

By Sean Whooley | December 1, 2020

Boston Scientific (NYSE:BSX) announced today that it entered into a definitive agreement to sell its BTG Specialty Pharmaceuticals business.

Marlborough, Mass.-based Boston Scientific is selling BTG for $800 million in cash to Stark International Lux S.A.R.L. and SERP SAS, both affiliates of European specialty pharmaceutical group SERB, according to a news release.

Get the full story at our sister site, MassDevice.

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].